兆科眼科(06622.HK)角膜上皮缺損藥II期臨牀試驗最後一名患者已入組
兆科眼科-B(06622.HK)公佈,公司核心產品ZKY001有關角膜上皮缺損適應症的第II期臨牀試驗的最後一名患者已於上星期五(21日)入組。
另外,集團與主要股東李氏大藥廠(00950.HK)附屬「李氏大藥廠(合 肥)」雙方同意提早終止主合約研究機構服務協議,自爲治療CED適應症的ZKY001第II期臨牀試驗完成日期(目前預期爲2022年第一季結束前)起生效。提早終止是由於環孢素A眼凝膠及鹽酸左倍他洛爾臨牀試驗的患者入組已於2021年完成,而隨ZKY001發掘額外新的適應症,應會進一步改變其持續臨牀試驗的設計。公司決定委派餘下臨牀試驗項目予其他獨立第三方服務提供商。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.